Dabigatran, fears in doctors’ minds.

Article Sidebar

PDF
Published: Feb 20, 2018
DOI: https://doi.org/10.31524/bkkmedj.2018.02.017

Main Article Content

Sant Chaiyodsilp, MD
Family physician and cardiac surgeon, Phyathai 2 Hospital, Bangkok, Thailand

Abstract

The fact that many doctors still refuse to replace the anticoagulant warfarin with dabigatran, despite dabigatran’s better safetyprofile, is not a scientific problem but a psychological one. In my view there are four fears in doctors’ minds:

Article Details

How to Cite
1.
Chaiyodsilp S. Dabigatran, fears in doctors’ minds. BKK Med J [internet]. 2018 Feb. 20 [cited 2026 Oct. 23];14(1):88. available from: https://he02.tci-thaijo.org/index.php/bkkmedj/article/view/222444
Issue
Vol. 14 No. 1 (2018): February
Section
Letter to The Editor
Creative Commons License

This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.

This article is published under the Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License (CC BY-NC-ND 4.0). You may copy and redistribute the material for noncommercial purposes, provided that appropriate credit is given and a link to the license is included. Modified versions may not be distributed under this license.

License: https://creativecommons.org/licenses/by-nc-nd/4.0/

References

1. US Food and Drug Administration. FDA Drug Safety Communication: Safety review of post-market reports of serious bleedingevents with the anticoagulant Pradaxa (dabigatran etexilate mesylate).2012 (Accessed September 13, 2017 at https://www.fda.gov/drugs/drugsafety/ucm282724.htm).
2. Australian Government, Department of Health and Aging, Therapeutic Goods Administration. Dabigatran (Pradaxa) and risk ofbleeding: Information for health professionals. 2013 (Accessed September 13, 2017 at https://www.tga.gov.au/alert/dabigatranpradaxa-and-risk-bleeding-information-health-professionals).
3. The Japanese Ministry of Health, Labor, and Welfare. Safety advisory of the potential for adverse events with dabigatran, November3, 2011. (Accessed September 13, 2012 at http://www.theheart.org/article/1264365.do).
4. Connolly SJ, Ezekowitz MD, Yusuf S, et.al. Dabigatran versus Warfarin in Patients with Atrial Fibrillation. N Engl J Med 2009;361:1139-51.
5. Camm AJ1, Lip GY, De Caterina R, et al. 2012 focused update of the ESC Guidelines for the management of atrial fibrillation: anupdate of the 2010 ESC Guidelines for the management of atrial fibrillation. Developed with the special contribution of the EuropeanHeart Rhythm Association. Eur Heart J 2012;33(21):2719-47.
6. Tomimori H, Yamamura N, Adachi T, et al. Pharmacokinetics, safety and pharmacodynamics after multiple oral doses of dabigatranetexilate capsule (110 mg and 150 mg b.i.d., 7 days) in healthy Japanese and Caucasian male subjects: An open label study. Studyno. 1160.61. Report no. U06-3420. Boehringer Ingelheim Internal Report, 2006.
7. Pollack CV Jr, Reilly PA, van Ryn J, et al. Idarucizumab for Dabigatran Reversal - Full Cohort Analysis. N Engl J Med 2017;377:431-41.